Vanguard Personalized Indexing Management
CORT icon

Vanguard Personalized Indexing Management’s Corcept Therapeutics CORT Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$754K Buy
8,676
+1,297
+18% +$78.3K 0.01% 1153
2026
Q1 		$297K Sell
7,379
-1,998
-21% -$74.7K ﹤0.01% 1612
2025
Q4 		$326K Sell
9,377
-176
-2% -$13.8K ﹤0.01% 1472
2025
Q3 		$794K Sell
9,553
-557
-6% -$40.3K 0.01% 1021
2025
Q2 		$742K Buy
10,110
+1,299
+15% +$94.2K 0.01% 1019
2025
Q1 		$1.01M Buy
8,811
+1,462
+20% +$89K 0.01% 780
2024
Q4 		$370K Buy
7,349
+184
+3% +$9.64K 0.01% 1245
2024
Q3 		$332K Buy
7,165
+840
+13% +$29.8K 0.01% 1297
2024
Q2 		$205K Buy
+6,325
New +$173K ﹤0.01% 1440
2024
Q1 		– Sell
-7,013
Closed -$228K – 1640
2023
Q4 		$228K Buy
+7,013
New +$193K 0.01% 1353
2023
Q1 		– Sell
-11,740
Closed -$238K – 1475
2022
Q4 		$238K Buy
+11,740
New +$294K 0.01% 1068

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Personalized Indexing Management's CORT Position: Q2 2026 in Review

Vanguard Personalized Indexing Management increased its Corcept Therapeutics (CORT) stake by 18% in Q2 2026, buying an estimated $78.3K and bringing the position to 8,676 shares worth $754K. The position accounts for 0.01% of the portfolio, ranked #1153.

Vanguard Personalized Indexing Management first reported a position in CORT in Q4 2022 and has held it in 11 quarters since. The position peaked at $1.01M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Vanguard Personalized Indexing Management held 8,676 shares of Corcept Therapeutics worth $754K as of Q2 2026.
  • Vanguard Personalized Indexing Management bought 1,297 Corcept Therapeutics shares in Q2 2026, an estimated $78.3K.
  • Corcept Therapeutics made up 0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #1153 holding.
  • Vanguard Personalized Indexing Management first reported a position in Corcept Therapeutics in Q4 2022 and has held it in 11 quarters since.
  • Vanguard Personalized Indexing Management's Corcept Therapeutics position peaked at $1.01M in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.